| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Traws Pharma, Inc. (TRAW) has 11 insiders with recent SEC Form 4 filings, including 4 buys and 11 sells. TRAW is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 597.7K | $508.2K | - | |
| COO | 150.6K | $128.1K | - | |
| CEO | 147.8K | $125.6K | - | |
| Other | 116.0K | $98.6K | - | |
| Other | 113.9K | $96.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 400 | $2.77 | $1,106.00 | - | |
| Sep 6, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 5,415 | $2.78 | $15,054.24 | -0.3% | |
| Jul 10, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 10,927 | $2.83 | $30,901.27 | -0.7% | |
| Jun 27, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 1,458 | $3.45 | $5,025.00 | -0.2% | |
| Jun 25, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 1,380 | $3.40 | $4,688.69 | -0.2% | |
| Aug 29, 2018 | Hoffman Michael B | Director | Sell | 99,999 | $0.45 | $45,187.67 | -0.4% | |
| May 29, 2018 | Bienen Henry S | Director | Buy | 10,000 | $0.38 | $3,800.00 | +78.6% | |
| Apr 27, 2018 | Marino James J | Director | Buy | 58,900 | $0.00 | - | +68.2% | |
| Apr 27, 2018 | Tyndall Capital Partners L P | 10% Owner | Buy | 10,147,058 | $0.42 | $4,312,499.65 | +483.9% | |
| Apr 27, 2018 | Stover Jack E | Director | Buy | 47,100 | $0.00 | - | +471,000% |